Ann Coloproctol.  2021 Apr;37(2):120-124. 10.3393/ac.2019.08.17.

An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient

• Song IG
• Jung KU
• Kim HO
• Kim H
• Chun HK

• KMID: 2515377
• DOI: http://doi.org/10.3393/ac.2019.08.17

Abstract

Everolimus (Afinitor) is an inhibitor of mammalian target of rapamycin. Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug that belongs to the cyclooxygenase-2 (COX-2) inhibitor family and is mainly used for treatment of arthritis. Intestinal perforation has not been reported previously as a complication of everolimus, and perforation of the lower intestinal tract caused by a selective COX-2 inhibitor is extremely rare. We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months.

Keyword

Colon perforation; Everolimus; mTOR inhibitor; Polmacoxib, Nonsteroidal anti-inflammatory agents